Affordable Prescriptions for Patients Act of 2023
- Introduced Jan 30
- Committee Jan 30
- Passed Senate Jul 11
- Passed House Next
- To President Not yet
- Law Not yet
Companies lobbying on this bill
8 companiesVotes
No recorded roll-call vote on this bill yet
Member trades
Summary
Affordable Prescriptions for Patients Act of 2023
Full summary2 paragraphs
This bill limits in certain instances the number of patents that a reference biological product manufacturer can assert in a patent infringement lawsuit against a company seeking to sell a biosimilar version.
Specifically, if the biosimilar manufacturer completes certain actions as part of an abbreviated pathway to get market approval, the bill limits, subject to exceptions and waivers, the number of certain types of patents that the reference product manufacturer may assert, such as patents filed more than four years after the reference product received market approval.
Library of Congress summary, Jul 11, 2024
- Passed SenateJul 11, 2024
- Reported to SenateMar 1, 2023
- Introduced in SenateJan 30, 2023
Actions
- HouseHeld at the desk.Jul 15, 2024
- HouseReceived in the House.Jul 15, 2024
- SenateMessage on Senate action sent to the House.Jul 12, 2024
- SenateMeasure laid before Senate by unanimous consent. (consideration: CR S4537-4538)Jul 11, 2024
- SenatePassed/agreed to in Senate: Passed Senate with an amendment by Unanimous Consent.Jul 11, 2024
- SenatePassed Senate with an amendment by Unanimous Consent. (text of amendment in the nature of a substitute: CR S4537-4538)Jul 11, 2024
- SenateCommittee on the Judiciary. Reported by Senator Durbin without amendment. Without written report.Mar 1, 2023
- SenatePlaced on Senate Legislative Calendar under General Orders. Calendar No. 22.Mar 1, 2023
- SenateCommittee on the Judiciary. Ordered to be reported without amendment favorably.Feb 9, 2023
- SenateIntroduced in SenateJan 30, 2023
- SenateRead twice and referred to the Committee on the Judiciary.Jan 30, 2023
Bill record
Text versions3
- Engrossed in SenateJul 11, 2024PDF: Engrossed in Senate
- Reported to SenateMar 1, 2023PDF: Reported to Senate
- Introduced in SenateJan 30, 2023PDF: Introduced in Senate
Committees1
- Senate Judiciary CommitteeReported By Mar 1, 2023Markup By, Feb 9, 2023Referred To, Jan 30, 2023
Sponsor and cosponsors8 cosponsors
- Sen. John Cornyn (R-TX)Sponsor, Jan 30, 2023
- Amy Klobuchar (D-MN)OriginalJoined Jan 30, 2023
- Chuck Grassley (R-IA)OriginalJoined Jan 30, 2023
- Richard Blumenthal (D-CT)OriginalJoined Jan 30, 2023
- Richard Durbin (D-IL)OriginalJoined Jan 30, 2023
- Ted Cruz (R-TX)OriginalJoined Jan 30, 2023
- Mike Braun (R-IN)Joined May 2, 2023
- Peter Welch (D-VT)Joined May 2, 2023
- Lisa Murkowski (R-AK)Joined Apr 9, 2024
Amendments1
- S.Amdt. 2399Jul 11, 2024In the nature of a substitute.Amendment SA 2399 agreed to in Senate by Unanimous Consent.
Cost estimates and reports1
- CBO: S. 150, Affordable Prescriptions for Patients Act of 2023Jun 13, 2024As reported by the Senate Committee on the Judiciary on March 1, 2023
Titles2
- Affordable Prescriptions for Patients Act of 2023Short Title(s) as Passed Senate
- A bill to amend the Federal Trade Commission Act to prohibit product hopping, and for other purposes.Official Title as Introduced
Subjects13
Related bills1
- S. 1435 117th, Reintroduction of Affordable Prescriptions for Patients Act of 2021
Official record from Congress.gov, the House Clerk and the Senate; lobbying from Lobbying Disclosure Act filings. Updated Oct 27, 2026.